Therapeutic dosimetry for Cf-252 neutron brachytherapy of pelvic cancer

Maruyama, Yosh; Beach, J.L.; Hazle, John D.; Ashtari, Manzar; Schroy, Carter B.; Olson, Michael M.

doi:10.1016/0360-3016(85)90115-4

Cited by 12 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typical isodose curves using Cf-NT for a tandem + ovoid insertion for a tandem plus ovoid and vaginal tube insertion have been published. 6 These have shown that the central cervical-uterine and paracervical dose in req are not distinguishable from gamma isodose curves.6…”

Section: Tumor Radiation Dosementioning

confidence: 99%

See 1 more Smart Citation

Phase I-II clinical trial of californium-252. Treatment of stage IB carcinoma of the cervix

Maruyama

Vannagell

Yoneda

et al. 1987

Cancer

Self Cite

View full text Add to dashboard Cite

Intracavitary Californium-252 combined with whole-pelvis photon radiotherapy was tested as the sole form of treatment for 22 patients with Stage IB carcinoma of the cervix. Californium-252 (Cf) is a fast neutron-emitting radioisotope currently being tested in trials of neutron brachytherapy (NT). The outcomes of the treated group of patients were traced for local tumor control, survival, patterns of failure, and complications. The Cf intracavitary therapy combined with whole-pelvis photon radiotherapy resulted in 95% 2-year and 91% 5-year actuarial survival. There were 9% Grade II-III complications by the Stockholm scale and 4% local failures. These results were obtained in an early clinical trial with a group of largely poor-risk patients with tumors of mean diameter of 4.3 cm.

show abstract

Section: Tumor Radiation Dosementioning

confidence: 99%

“…6 These have shown that the central cervical-uterine and paracervical dose in req are not distinguishable from gamma isodose curves.6…”

Section: Tumor Radiation Dosementioning

confidence: 99%

Phase I-II clinical trial of californium-252. Treatment of stage IB carcinoma of the cervix

Maruyama

Vannagell

Yoneda

et al. 1987

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Feasibility study of californium-252 for the therapy of stage IV cervical cancer

Maruyama

Nagell

Yoneda

et al. 1988

Cancer

View full text Add to dashboard Cite

Twenty patients with Stage IVA and IVB cervic cancers were treated with Californium-252 (Cf) neutron brachytherapy (NT) in a feasibility trial between 1976 and 1986. Eleven patients had Stage IVA disease; nine patients had Stage IVB disease. Patient compliance with therapy was poor in four of nine patients with Stage IVB disease, and the 50% survival time was 6 months. In Stage IVA disease there were 18% 3-year survivals. For those that failed, the 50% survival time was 7.5 months. Because of the frequency of disseminated metastases, effective adjuvant therapy needs to be developed to use after the tumor debulking therapy, especially for Stage IVB disease. A single early Cf-NT implant followed by 6000 cGy of whole-pelvis fractionated radiation would accomplish this adequately for local tumor control and palliation.

show abstract